Top

Supportive Care in Cancer

Published in:

01-09-2019 | Prostate Cancer | Original Article

Problems sleeping with prostate cancer: exploring possible risk factors for sleep disturbance in a population-based sample of survivors

Authors: Rebecca Maguire, Frances J. Drummond, Paul Hanly, Anna Gavin, Linda Sharp

Published in: Supportive Care in Cancer | Issue 9/2019

Abstract

Purpose

This study aimed to investigate the prevalence of sleeping problems in prostate cancer survivors and to explore the role of predisposing, precipitating and perpetuating factors in this process.

Methods

Using a cross-sectional design, 3348 prostate cancer survivors between 2 and 18 years post diagnosis reported experiences of insomnia using the QLQC30, along with their sociodemographic characteristics, health status and treatment(s) received. The EQ5D-5L and QLQPR25 assessed survivors’ overall and prostate cancer–specific health-related quality of life. A hierarchical multiple regression analysis was constructed with three blocks: (1) predisposing (e.g. demographics at diagnosis), (2) precipitating (e.g. disease extent, treatment) and (3) perpetuating factors (e.g. side effects).

Results

Nineteen percent of survivors reported significant problems sleeping. The final model accounted for 31% of the variance in insomnia scores (p < .001). In order of magnitude, associates of sleep disturbance were urinary symptoms (β = 0.22; p < .001), experiencing symptoms of depression/anxiety (β = 0.18; p < .001), hormone treatment–related symptoms (β = 0.12; p = .001), pain (β = 0.10; p < .001) and bowel symptoms (β = 0.06; p = .005). Having a lower education and more comorbidities at diagnosis also predicted sleep problems.

Conclusion

Results suggest that it is the ongoing adverse effects of prostate cancer and its treatment (e.g. urinary symptoms) that put survivors most at risk of sleep problems. Strong associations with symptoms of depression/anxiety were also observed. Findings highlight the need for health care practitioners to treat and manage adverse effects of prostate cancer treatment in order to mitigate sleep disturbance in survivors.

Available only for authorised users

Drummond F, Kinnear H, O’Leary E, Donnelly GA, Sharp L (2015) Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. J Cancer Surviv 9(2):361–372. https://doi.org/10.1007/s11764-014-0419-6 CrossRefPubMed

Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12):1250–1261. https://doi.org/10.1056/NEJMoa074311 CrossRefPubMed

Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH (1995) Quality-of-life outcomes in men treated for localized prostate cancer. Jama 273(2):129–135CrossRefPubMed

Drummond FJ (2016) Are we sleeping on the job? Insomnia among men with prostate cancer. Adv Mod Oncol Res 2:74CrossRef

Roscoe JA, Kaufman ME, Matteson-Rusby SE, Palesh OG, Ryan JL, Kohli S, Perlis ML, Morrow GR (2007) Cancer-related fatigue and sleep disorders. Oncologist 12(Suppl 1):35–42. https://doi.org/10.1634/theoncologist.12-S1-35 CrossRefPubMed

Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM (2011) Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. J Clin Oncol 29(26):3580–3586. https://doi.org/10.1200/jco.2010.33.2247 CrossRefPubMed

Zhou ES, Partridge AH, Syrjala KL, Michaud AL, Recklitis CJ (2017) Evaluation and treatment of insomnia in adult cancer survivorship programs. J Cancer Surviv 11(1):74–79. https://doi.org/10.1007/s11764-016-0564-1 CrossRefPubMed

Dirksen SR, Epstein DR, Hoyt MA (2009) Insomnia, depression, and distress among outpatients with prostate cancer. Appl Nurs Res 22(3):154–158. https://doi.org/10.1016/j.apnr.2007.09.001 CrossRefPubMed

Savard J, Simard S, Hervouet S, Ivers H, Lacombe L, Fradet Y (2005) Insomnia in men treated with radical prostatectomy for prostate cancer. Psychooncology 14(2):147–156. https://doi.org/10.1002/pon.830 CrossRefPubMed

10.

Mystakidou K, Parpa E, Tsilika E, Pathiaki M, Patiraki E, Galanos A, Vlahos L (2007) Sleep quality in advanced cancer patients. J Psychosom Res 62(5):527–533. https://doi.org/10.1016/j.jpsychores.2006.11.008 CrossRefPubMed

11.

Roth T, Franklin M, Bramley TJ (2007) The state of insomnia and emerging trends. Am J Manag Care 13(5 Suppl):S117–S120PubMed

12.

Savard J, Ivers H, Savard MH, Morin CM (2015) Cancer treatments and their side effects are associated with aggravation of insomnia: results of a longitudinal study. Cancer 121(10):1703–1711. https://doi.org/10.1002/cncr.29244 CrossRefPubMed

13.

Savard J, Hervouet S, Ivers H (2013) Prostate cancer treatments and their side effects are associated with increased insomnia. Psychooncology 22(6):1381–1388. https://doi.org/10.1002/pon.3150 CrossRefPubMed

14.

Miaskowski C, Paul SM, Cooper BA, Lee K, Dodd M, West C, Aouizerat BE, Dunn L, Swift PS, Wara W (2011) Predictors of the trajectories of self-reported sleep disturbance in men with prostate cancer during and following radiation therapy. Sleep 34(2):171–179CrossRefPubMedPubMedCentral

15.

Mercadante S, Aielli F, Adile C, Ferrera P, Valle A, Cartoni C, Pizzuto M, Caruselli A, Parsi R, Cortegiani A, Masedu F, Valenti M, Ficorella C, Porzio G (2015) Sleep disturbances in patients with advanced cancer in different palliative care settings. J Pain Symptom Manag 50(6):786–792. https://doi.org/10.1016/j.jpainsymman.2015.06.018 CrossRef

16.

Singareddy R, Vgontzas AN, Fernandez-Mendoza J, Liao D, Calhoun S, Shaffer ML, Bixler EO (2012) Risk factors for incident chronic insomnia: a general population prospective study. Sleep Med 13(4):346–353. https://doi.org/10.1016/j.sleep.2011.10.033 CrossRefPubMedPubMedCentral

17.

Spielman AJ, Caruso LS, Glovinsky PB (1987) A behavioral perspective on insomnia treatment. Psychiatr Clin 10(4):541–553

18.

Fiorentino L, Rissling M, Liu L, Ancoli-Israel S (2011) The symptom cluster of sleep, fatigue and depressive symptoms in breast cancer patients: severity of the problem and treatment options. Drug Discov Today Dis Model 8(4):167–173CrossRef

19.

Savard J, Morin CM (2001) Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 19(3):895–908CrossRefPubMed

20.

Savard J, Villa J, Ivers H, Simard S, Morin CM (2009) Prevalence, natural course, and risk factors of insomnia comorbid with cancer over a 2-month period. J Clin Oncol 27(31):5233–5239CrossRefPubMed

21.

Garland SN, Barg FK, Cakouros B, Gehrman P, DuHamel KN, Mao JJ (2018) A qualitative examination of the factors related to the development and maintenance of insomnia in cancer survivors. Palliat Support Care:1–6. https://doi.org/10.1017/S1478951518000135

22.

Sivertsen B, Salo P, Mykletun A, Hysing M, Pallesen S, Krokstad S, Nordhus IH, Overland S (2012) The bidirectional association between depression and insomnia: the HUNT study. Psychosom Med 74(7):758–765. https://doi.org/10.1097/PSY.0b013e3182648619 CrossRefPubMed

23.

LeBlanc M, Merette C, Savard J, Ivers H, Baillargeon L, Morin CM (2009) Incidence and risk factors of insomnia in a population-based sample. Sleep 32(8):1027–1037CrossRefPubMedPubMedCentral

24.

Maguire R, Hanly P, Drummond FJ, Gavin A, Sharp L (2018) Expecting the worst? The relationship between retrospective and prospective appraisals of illness on quality of life in prostate cancer survivors. Psychooncology 27(4):1237–1243. https://doi.org/10.1002/pon.4660 CrossRefPubMed

25.

Drummond F, Kinnear H, Donnelly C, O’Leary E, O’Brien K, Burns R, Gavin A, Sharp L (2015) Establishing a population-based patient-reported outcomes study (PROMs) using national cancer registries across two jurisdictions: the prostate cancer treatment, your experience (PiCTure) study. BMJ Open 5(4):e006851. https://doi.org/10.1136/bmjopen-2014-006851 CrossRefPubMedPubMedCentral

26.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefPubMed

27.

Steentjes L, Siesling S, Drummond FJ, van Manen JG, Sharp L, Gavin A (2016) Factors associated with current and severe physical side-effects after prostate cancer treatment: what men report. Eur J Cancer Care (Engl) 27. https://doi.org/10.1111/ecc.12589

28.

van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, D’Haese S, Aaronson NK (2008) An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 44(16):2418–2424. https://doi.org/10.1016/j.ejca.2008.07.030 CrossRefPubMed

29.

O’Leary E, Drummond FJ, Gavin A, Kinnear H, Sharp L (2015) Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curate’s egg. Qual Life Res 24(9):2219–2230. https://doi.org/10.1007/s11136-015-0958-y CrossRefPubMed

30.

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727–1736. https://doi.org/10.1007/s11136-011-9903-x CrossRefPubMedPubMedCentral

31.

Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S (2007) Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 45:259–263CrossRefPubMed

32.

Juul T, Petersen MA, Holzner B, Laurberg S, Christensen P, Grønvold M (2014) Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity. Qual Life Res 23(8):2183–2193CrossRefPubMed

33.

Waldmann A, Schubert D, Katalinic A (2013) Normative data of the EORTC QLQ-C30 for the German population: a population-based survey. PLoS One 8(9):e74149CrossRefPubMedPubMedCentral

34.

Li X, Wong W, Lamoureux EL, Wong TY (2012) Are linear regression techniques appropriate for analysis when the dependent (outcome) variable is not normally distributed? Invest Ophthalmol Vis Sci 53(6):3082–3083CrossRefPubMed

35.

Scott NW, Fayers P, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, Gundy C, Koller M, Petersen MA, Sprangers MA (2008) EORTC QLQ-C30 reference values manual

36.

Drummond FJ, Gavin AT, Sharp L (2017) Supportive medications and interventions received by prostate cancer survivors: results from the PiCTure study. J Community Support Oncol 15(6):e309–e313CrossRef

37.

Knutson K (2015) Sleep and pain: summary of the 2015 sleep in America poll. Sleep Health 1(2):85. https://doi.org/10.1016/j.sleh.2015.03.006 CrossRefPubMed

38.

Hoyt MA, Bower JE, Irwin MR, Weierich MR, Stanton AL (2016) Sleep quality and depressive symptoms after prostate cancer: the mechanistic role of cortisol. Behav Neurosci 130(3):351–356CrossRefPubMedPubMedCentral

39.

Sharp L, O’Leary E, Kinnear H, Gavin A, Drummond FJ (2016) Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: results from the PiCTure study. Psychooncology 25(3):282–291. https://doi.org/10.1002/pon.3909 CrossRefPubMed

40.

Watts S, Leydon G, Birch B, Prescott P, Lai L, Eardley S, Lewith G (2014) Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 4(3):e003901. https://doi.org/10.1136/bmjopen-2013-003901 CrossRefPubMedPubMedCentral

41.

Maguire R, Hanly P, Drummond F, Gavin A, Sharp L (2017) Regret and fear in prostate cancer: the relationship between treatment appraisals and fear of recurrence in prostate cancer survivors. Psycho-Oncology 26(11):1825–1831. https://doi.org/10.1002/pon.4384 CrossRefPubMed

42.

Cordova MJ, Riba MB, Spiegel D (2017) Post-traumatic stress disorder and cancer. Lancet Psychiatry 4(4):330–338. https://doi.org/10.1016/s2215-0366(17)30014-7 CrossRefPubMedPubMedCentral

43.

Pigeon WR, Campbell CE, Possemato K, Ouimette P (2013) Longitudinal relationships of insomnia, nightmares, and PTSD severity in recent combat veterans. J Psychosom Res 75(6):546–550. https://doi.org/10.1016/j.jpsychores.2013.09.004 CrossRefPubMed

44.

Johnson JA, Rash JA, Campbell TS, Savard J, Gehrman PR, Perlis M, Carlson LE, Garland SN (2016) A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors. Sleep Med Rev 27:20–28. https://doi.org/10.1016/j.smrv.2015.07.001 CrossRefPubMed

Title: Problems sleeping with prostate cancer: exploring possible risk factors for sleep disturbance in a population-based sample of survivors
Authors: Rebecca Maguire
Frances J. Drummond
Paul Hanly
Anna Gavin
Linda Sharp
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Insomnia
Affective Disorder
Prostate Cancer
Affective Disorder
Anxiety
Published in: Supportive Care in Cancer / Issue 9/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4633-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2019

Correction to: High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes

Evaluation of a community-based dental screening program prior to radiotherapy for head and neck cancer: a single-center experience

Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence

Pharmacological evidence of medicinal cannabis in oncology: a systematic review

Web-based videoconferencing for rural palliative care consultation with elderly patients at home

Effect of acupressure on constipation in patients with advanced cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer